The irreversible EGFR tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in patients with advanced colorectal cancer (ACC): A phase I/IIa pharmacokinetic and serial skin and tumor pharmacodynamic study

Research output: Contribution to journal › Meeting abstract › Contributed › peer-review

Contributors

  • Gunnar Folprecht - , Department of internal Medicine I (Author)
  • Josep Tabernero - , Vall d'Hebron University Hospital (Author)
  • Luis Paz-Ares - , Hospital Universitario 12 de Octubre (Author)
  • Jose Baselga - , Vall d'Hebron University Hospital (Author)
  • Hernan Cortes-Funes - , Hospital Universitario 12 de Octubre (Author)
  • Esther Casado - , Vall d'Hebron University Hospital (Author)
  • Federico Rojo - , Vall d'Hebron University Hospital (Author)
  • Jean-Michel Vauthier - , Pfizer (Author)
  • Charles Zacharchuk - , Pfizer (Author)
  • Claus-Henning Koehne - , TUD Dresden University of Technology (Author)

Details

Original languageEnglish
Pages (from-to)85-85
Number of pages1
JournalAnnals of oncology
Volume15
Publication statusPublished - 2004
Peer-reviewedYes

External IDs

ORCID /0000-0002-9321-9911/work/142252041

Keywords

Sustainable Development Goals